Coeptis Therapeutics Holdings, Inc. (COEP) Financial Statements
Industry: Finance Services
In fiscal 2025, Coeptis Therapeutics reported revenue of $1.4M. Net income was -$11.9M (a -874.3% net margin), or -$2.81 per diluted share. Gross margin was 86.7% and operating margin was -956.9%. Operating activities generated -$8.6M of cash. At fiscal year end, Coeptis Therapeutics held $16.2M in total assets against $2.1M in total liabilities.
Open the full interactive Coeptis Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Coeptis Therapeutics Key Stats
| Share Price | $5.16 |
|---|---|
| Market Cap | $257.0M |
| 52-Week Range | $2.29 – $18.80 |
| Shares Outstanding | 49.8 million (basic, 2026 Q2) |
Coeptis Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.4M |
| Cost of Goods Sold | $0 | $0 | — | — | — | — |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $1.2M |
| Operating Income | -$68,430 | -$681,319 | -$34.2M | -$21.5M | -$10.1M | -$13.0M |
| Pre-Tax Income | -$67,226 | $15.2M | -$37.6M | -$21.3M | -$10.9M | -$12.3M |
| Income Tax | — | — | $0 | $0 | $0 | $0 |
| Net Income | -$67,226 | $15.2M | -$37.6M | -$21.3M | -$10.9M | -$11.9M |
| Diluted EPS | -$0.60 | — | -$52.60 | -$16.60 | -$5.65 | -$2.81 |
Coeptis Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $237,441 | $862,049 | $113,771 | $1.6M |
| Net Income | -$2.9M | -$1.3M | -$4.0M | -$13.8M |
| Diluted EPS | -$0.58 | -$0.30 | -$0.65 | -$0.28 |
Coeptis Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $907,184 | $404,345 | — | — | — | — |
| Current Assets | $958,999 | $412,678 | $3.9M | $5.2M | $1.1M | $7.4M |
| Total Assets | $76.7M | $76.2M | $7.9M | $8.1M | $8.9M | $16.2M |
| Current Liabilities | $5,000 | $139,927 | $1.8M | $3.0M | $4.5M | $1.8M |
| Total Long-Term Debt | — | — | $150,000 | $1.1M | $1.5M | $150,000 |
| Total Liabilities | $2.3M | $7.2M | $3.1M | $3.8M | $5.0M | $2.1M |
| Shareholders' Equity | $5.0M | -$6.8M | $4.8M | $4.3M | $3.2M | $13.6M |
Coeptis Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$115,695 | -$502,839 | -$3.9M | -$7.2M | -$6.6M | -$8.6M |
| Cash From Investing | -$75.8M | — | $0 | $0 | $0 | $0 |
| Cash From Financing | $76.8M | — | $5.5M | $4.9M | $5.7M | $13.7M |
Figures from Coeptis Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Coeptis Therapeutics financials page for every line item.
Coeptis Therapeutics Company Profile
| Ticker | COEP |
|---|---|
| Exchange | Nasdaq |
| Industry | Finance Services |
| Headquarters | Fort Lauderdale, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001759186 |
Frequently Asked Questions
What was Coeptis Therapeutics' revenue in fiscal 2025?
Coeptis Therapeutics (COEP) reported revenue of $1.4M for fiscal 2025.
What is Coeptis Therapeutics' annual revenue history?
Coeptis Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $1.4M.
What was Coeptis Therapeutics' net income in fiscal 2025?
Coeptis Therapeutics reported net income of -$11.9M for fiscal 2025.
What was Coeptis Therapeutics' earnings per share (EPS) in fiscal 2025?
Coeptis Therapeutics' diluted EPS was -$2.81 for fiscal 2025 (adjusted for any later stock splits).
What was Coeptis Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Coeptis Therapeutics reported revenue of $1.6M.
How much debt does Coeptis Therapeutics have?
Coeptis Therapeutics reported $150,000 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Coeptis Therapeutics are outstanding?
Coeptis Therapeutics reported a weighted average of 49.8 million basic shares outstanding in 2026 Q2.
What is Coeptis Therapeutics' market cap?
Based on its latest closing price, Coeptis Therapeutics (COEP) has a market capitalization of about $257.0M.
When does Coeptis Therapeutics' fiscal year end?
Coeptis Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Coeptis Therapeutics headquartered?
Coeptis Therapeutics lists its business address in Fort Lauderdale, Florida in its SEC filings.